# Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)

Study · id `cardio:ct-nct07304817` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07304817](<https://clinicaltrials.gov/study/NCT07304817>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07304817

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT07304817. Randomized; single masking; primary purpose other. Start 2026-05-12 (actual); primary completion 2028-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose other
- Phase: Phase 2
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT07304817, source copy `cardio:ctgov-nct07304817-2026-05-29`, retrieved 2026-10-26)
- Started: 2026-05-12 (actual) (ClinicalTrials.gov record NCT07304817, source copy `cardio:ctgov-nct07304817-2026-05-29`, retrieved 2026-10-26)
- Primary completion: 2028-02 (anticipated) (ClinicalTrials.gov record NCT07304817, source copy `cardio:ctgov-nct07304817-2026-05-29`, retrieved 2026-10-26)
- Completion: 2028-02 (anticipated) (ClinicalTrials.gov record NCT07304817, source copy `cardio:ctgov-nct07304817-2026-05-29`, retrieved 2026-10-26)
- Countries: Netherlands (ClinicalTrials.gov record NCT07304817, source copy `cardio:ctgov-nct07304817-2026-05-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07304817-2026-05-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)
- Acronym: COMPARE-VS
- Condition: CKD
- Condition: Cardiovascular Diseases
- Condition: Heart Failure
- Intervention (Drug): vicadrostat / empagliflozin combination 1
- Intervention (Drug): Spironolactone (drug)
- Lead sponsor: University Medical Center Groningen
- Lead sponsor class: OTHER
- Collaborator: Boehringer Ingelheim
- Collaborator class: INDUSTRY
- Collaborator: DELPHINIUM
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: University Medical Center Groningen (`cardio:org-university-medical-center-groningen`)
- Registry lists this organization as a collaborator: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

## Provenance

Content hash: 92bd3c62ada05df873d0114c77e4f984718b2997408e3b8500e8c3cbe74654ed
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
